A Gut Metabolite Blocked the Liver Cell Death Behind Surgery Injury

If you are reading about liver health because of your own lab results, an operation on the calendar, or someone you love waiting on a transplant, here is a problem patients rarely get told about plainly. Liver surgery has to injure the liver: surgeons interrupt blood flow to operate, and when they restore it the tissue attacks itself, a process called ischemia-reperfusion injury. A new study reports that a small molecule your own gut bacteria make from ordinary plant compounds blunted that damage in human liver tissue grown in a dish and in living mice, and it pins down the exact form of cell death it switches off.

Key Takeaways

• Desaminotyrosine (DAT), a molecule gut bacteria make from dietary flavonoids, reduced liver injury in human liver organoids and in mice after blood flow was cut off and restored.
• It worked by quieting the MAPK signaling pathway and blocking ferroptosis, an iron-dependent form of cell death, while raising the protective proteins GPX4 and Nrf2.
• Part of the benefit ran through the gut itself. DAT enriched Bifidobacterium pseudolongum, and mice whose microbiota had been stripped out lost the protection.
• This is preclinical work. No patients were treated, DAT's direct target inside liver cells is still unidentified, and only male mice were studied.

Desaminotyrosine, a Gut Flavonoid Metabolite, Blunted Liver Ischemia-Reperfusion Injury

Desaminotyrosine, abbreviated DAT, is a small molecule that intestinal bacteria produce when they break down flavonoids (plant compounds abundant in fruit, vegetables and tea), and in this work it reduced liver damage caused by interrupted and restored blood flow in both human liver organoids and mice. The study, by Junyang Zhou and colleagues at Hubei University of Medicine, appears in Pharmacological Research. Mice pretreated with DAT before surgery showed lower serum AST and ALT (two enzymes that leak into the blood when liver cells are damaged), less destruction on stained tissue sections, fewer dying cells, and lower liver expression of the inflammatory messengers TNF-alpha, IL-6 and IL-1beta.

DAT is not new to microbiome researchers. It became notable in 2017, when a team showed that the same metabolite protects mice from influenza by boosting type I interferon signaling. What is new here is a different organ, a different mechanism, and a named bacterium doing much of the work.

Hepatectomy and Transplant Patients Carry the Real-World Stakes

The people this matters to are those facing liver resection or liver transplantation, where ischemia-reperfusion is, in the authors' framing, common and unavoidable, and where it meaningfully worsens patient prognosis. Clinical measures to prevent it remain very limited, which is why a cheap, low-toxicity molecule draws attention. The underlying problem is well documented: ischemia-reperfusion injury is a central determinant of how a transplanted liver performs, and it is part of why some donor organs never function properly. If you or a family member is being evaluated for transplant, the NIDDK patient overview of liver transplantation explains where this injury sits in the procedure.

Human Organoids, Clamped Mouse Livers and Antibiotic-Wiped Guts

The credibility here comes from stacking three model systems rather than leaning on one. Liver organoids (three-dimensional mini-tissues) were grown from normal liver tissue taken from people undergoing liver resection at Taihe Hospital, then pushed through 48 hours of hypoxia followed by 6 hours of reoxygenation, with DAT added 12 hours ahead at 1 or 5 mM. Male C57BL/6 mice aged 8 to 10 weeks received DAT at 50 mg/kg by intraperitoneal injection for 3 consecutive days, then underwent 1.5 hours of clamped liver ischemia and 6 hours of reperfusion, against sham animals given the same surgery without the clamp. Third, a pseudo-germ-free group had its microbiota stripped with a vancomycin, neomycin, metronidazole and amikacin cocktail in the drinking water for 14 days.

That third arm is what makes the interpretation stick. With the microbiota gone, DAT's protection fell away, which is how the authors establish the effect is gut-microbiota-dependent rather than purely pharmacological.

The MAPK and Ferroptosis Axis Splits Along Liver Zones

DAT protected liver cells by suppressing ferroptosis, and spatial mapping showed it does so differently in different regions of the liver lobule. Ferroptosis is an iron-dependent form of cell death driven by lipid peroxidation, distinct from apoptosis, and it has become one of the most actively studied cell death programs in organ injury. Using spatial transcriptomics and spatial metabolomics with zonation markers (Cyp2f2 for portal vein zones, Cyp2e1 for central vein zones), the team found DAT reshaped MAPK signaling and ferroptosis gene expression specifically in the portal vein zones, while in the central vein zones it pushed up taurine and hypotaurine metabolism and pulled down arachidonic acid, a fatty acid that feeds ferroptosis. Downstream, the antioxidant defenses GPX4 and Nrf2 rose.

Two experiments make that causal chain hard to wave away. Giving RSL3, a drug that forces ferroptosis, cancelled DAT's protection in both mice and organoids. And combining DAT with inhibitors of ERK, p38 and JNK increased cell death compared with DAT alone, tying the benefit to intact MAPK signaling rather than to a generic antioxidant effect.

Bifidobacterium pseudolongum Is the Bacterium Doing the Work

The specific microbe DAT enriches is Bifidobacterium pseudolongum. 16S rRNA gene sequencing of mouse feces (n = 5 animals per group) flagged it as the standout genus-level difference between injured mice and injured mice given DAT, and DAT sped up its growth in culture in a dose-dependent way. Transplanting live B. pseudolongum into antibiotic-treated mice reproduced the protection, while heat-inactivated bacteria did nothing, ruling out a simple reaction to bacterial debris. Most striking, B. pseudolongum grown with DAT outperformed the plain live bacterium, and even the culture medium from DAT-treated bacteria reduced cell death and improved liver function, pointing to a bacterial product as the final messenger.

What This Does and Does Not Mean If You Are Facing Liver Surgery

Nothing here changes what you should take. DAT is not an approved drug, the doses used were injected into mice or applied to tissue in a dish, and no patient was treated, so there is no basis for buying a flavonoid supplement or a Bifidobacterium product on the strength of it. The honest reading is narrower and still useful: this identifies a plausible, testable pre-surgical intervention, and it strengthens the case that gut microbial composition shapes how well an organ tolerates surgical stress. If you have an operation scheduled, the thing worth raising with your surgical team is what they already do to limit reperfusion injury, not this compound.

Unanswered Questions for DAT, and What Comes Next

The authors list their own limits, and they are the right ones. DAT's direct molecular target inside liver cells is still unidentified, so nobody knows what it physically binds. The relative contribution of the direct MAPK and ferroptosis route versus the microbiota route has not been quantified, and it may differ between acute and chronic injury. Sex-specific differences were not examined at all, since only male mice were used. The 48 hours of hypoxia the organoids endured is also far slower than the ischemia of real surgery, a trade-off the authors acknowledge and attribute to how slowly organoids metabolize. The paper declares no competing interests and lists government research funding.

From here the authors position DAT as a candidate for pre-transplant or pre-surgical intervention, and B. pseudolongum as a candidate probiotic for preventing liver ischemia-reperfusion injury. Before either reaches a clinic, the near-term work is chemical: affinity purification and proteomics to find DAT's binding partner, then dosing and safety work, then experiments that separate the direct liver effect from the microbiota effect. Human trials would eventually have to show that pretreating a transplant or resection patient improves how the liver actually performs, and no data yet speak to that.

Common Questions

Is desaminotyrosine something I can buy or eat? DAT is made by your gut bacteria from dietary flavonoids rather than eaten directly, and it is not sold as an approved therapy. This study injected it into mice at a fixed dose and applied it to cells in culture, neither of which tells you anything about oral supplements in people.

Would eating more flavonoids raise my DAT levels? The study did not test diet. It builds on the established background that intestinal bacteria convert dietary flavonoids into DAT, and it showed that giving DAT directly enriched Bifidobacterium pseudolongum in mice. Whether food-level flavonoid intake shifts DAT enough to matter is untested here.

What is ferroptosis, and why does it matter for the liver? Ferroptosis is a form of cell death in which iron drives runaway oxidation of the fats in cell membranes, and it is a major contributor to the damage liver tissue sustains when blood flow returns after being cut off. Shutting it down is the specific thing DAT appeared to do in this work.

Should I look for Bifidobacterium pseudolongum in a probiotic? No. This study delivered a cultured strain directly into microbiota-depleted mice, which is not comparable to swallowing a supplement, and the authors describe the species only as a candidate probiotic: a starting point for development, not a product recommendation.

References

Junyang Zhou, Man Luo, Ping Zhu, et al. (2026). Desaminotyrosine Alleviates Hepatic Ischemia-Reperfusion Injury via the MAPK/Ferroptosis Axis and Bifidobacterium pseudolongum Modulation. Pharmacological Research. https://doi.org/10.1016/j.phrs.2026.108389

Steed, A.L., et al. (2017). The microbial metabolite desaminotyrosine protects from influenza through type I interferon. Science, 357(6350), 498-502. https://www.science.org/doi/10.1126/science.aam5336

Ischaemia-reperfusion injury in liver transplantation: from bench to bedside (2013). Nature Reviews Gastroenterology & Hepatology. https://www.nature.com/articles/nrgastro.2012.225

Dixon, S.J., et al. (2012). Ferroptosis: an iron-dependent form of nonapoptotic cell death. Cell. https://pubmed.ncbi.nlm.nih.gov/22632970/

Jiang, X., et al. (2021). Ferroptosis: mechanisms, biology and role in disease. Nature Reviews Molecular Cell Biology, 22(4), 266-282. https://www.nature.com/articles/s41580-020-00324-8

National Institute of Diabetes and Digestive and Kidney Diseases. Liver Transplant. https://www.niddk.nih.gov/health-information/liver-disease/liver-transplant